Canadian Owned & OperatedFree Shipping Over $299TRY OUR new GHK-CU skin care line
Pure Peptides Canada
0
Research Library

Brown Adipose Tissue and Thermogenesis

October 11, 2026 · Metabolic Research, Education · 25 min read

Branching ice crystals spread across a window pane with soft daylight behind them

Brown fat is the most appealing idea in metabolic research: a tissue whose entire job is to burn fuel and waste the energy as heat. If you could switch it on at will, the reasoning goes, you would have a metabolic intervention that works by addition rather than restriction. That reasoning is why “thermogenic” became a marketing word, and it is also why a great deal of what gets said about brown fat does not match the papers.

This guide covers how adult human brown fat was confirmed, what UCP1 actually does and when, the difference between brown and beige fat, why the standard imaging method does not measure what people think it measures, how much energy brown fat is actually measured to burn, and which of the compounds routinely filed under “thermogenic” have any published connection to it. The last answer is the shortest.

The short answer

  • Adult humans do have functional brown fat, confirmed by three papers published in the same 2009 issue of the New England Journal of Medicine. In one, cold exposure activated brown fat in 23 of 24 healthy men; in another, substantial brown fat was detectable in 7.5% of women and 3.1% of men on routine scans.
  • UCP1 is the mechanism. It is a carrier in the mitochondrial inner membrane that lets protons back into the matrix, dissipating the proton-motive force as heat instead of using it to make ATP.
  • UCP1 does not leak constantly. It requires activation, typically by free fatty acids released during lipolysis — the title of a 2022 paper puts it as: uncoupling protein 1 does not produce heat without activation.
  • More UCP1 does not simply mean leaner. UCP1-knockout mice are cold-sensitive but, in the words of the 1997 paper’s own title, not obese — on a standard diet or a high-fat one.
  • Which adrenergic receptor matters in humans is unsettled. Beta-3 agonists activate brown fat in people, yet a 2020 study of cultured human brown adipocytes argued that beta-1, not beta-3, may be the primary regulator.
  • The imaging does not measure heat. FDG-PET measures glucose uptake, and a 2018 review states plainly that brown fat glucose metabolism does not accurately reflect its thermogenic activity — roughly half the glucose taken up is released as lactate.
  • The measured energy numbers are small. Direct estimates put brown fat’s contribution at roughly 7 to 25 kcal per day, with speculative upper bounds in the low hundreds that depend entirely on an uncertain volume estimate.
  • No drug is approved anywhere that works by activating brown fat. The beta-3 agonist used in every positive human study is approved only for bladder indications, and the dose that activated brown fat exceeded the approved maximum, with the investigators warning it may confer too great a cardiovascular risk.
  • None of the compounds commonly sold as thermogenic acts on brown fat. Not 5-Amino-1MQ, not SLU-PP-332, not AOD-9604, not adipotide. We went through the primary papers; the detail is below.

Brown adipose tissue

BAT · brown fat · the UCP1-expressing thermogenic depot

What it is
An adipose depot whose mitochondria can uncouple substrate oxidation from ATP synthesis, producing heat
Key protein
UCP1, also called thermogenin; a carrier in the mitochondrial inner membrane
Confirmed in adults
2009, by three independent studies in one issue of the New England Journal of Medicine
Main depots
Neck and supraclavicular, plus paracervical; biopsies show multilocular, UCP1-positive adipocytes
Activation
Cold, through sympathetic adrenergic signalling; UCP1 itself needs free fatty acids from lipolysis
Measured by
Cold-stimulated 18F-FDG PET/CT — a glucose-uptake proxy, not a heat measurement
Volume in adults
Under about 150 ml of FDG-positive tissue in most healthy individuals, probably an underestimate
Drugs approved via this mechanism
None, anywhere

Where the evidence stands

  1. Cell and rodent studies
  2. Human imaging studies
  3. Small human pharmacology trials
  4. An approved brown-fat-targeted medicine

That adult humans have functional brown fat is settled. That it can be used therapeutically is not, and the dose needed in the only drug tested raised cardiovascular concerns.

What brown fat is

White adipose tissue stores energy. Brown adipose tissue spends it, deliberately, as heat. The colour comes from mitochondrial density and vascularisation, and the cells look different under a microscope: brown adipocytes hold many small lipid droplets rather than one large one, which is what “multilocular” means in the biopsy descriptions below.

Its original, uncontroversial job is non-shivering thermogenesis — keeping a small mammal, or a human infant, warm without muscle contraction. The interesting question, and the one that reopened the field around 2009, is whether adults retain enough of it to matter metabolically.

How adult human brown fat was confirmed

For decades the textbook position was that brown fat was essentially an infant tissue. Three papers in the 8 April 2009 issue of the New England Journal of Medicine — consecutively paginated, which is unusual and tells you the editors knew what they had — changed that.

StudyDesignWhat it found
Cypess and colleaguesRetrospective review of 3,640 FDG-PET/CT scans from 1,972 patientsSubstantial brown fat in 7.5% of women and 3.1% of men. Neck and supraclavicular biopsies showed UCP1-positive multilocular adipocytes. Presence was inversely associated with age, outdoor temperature, beta-blocker use and BMI
van Marken Lichtenbelt and colleagues24 healthy young men (10 lean, 14 overweight or obese), scanned at thermoneutral 22 °C and at mild cold, 16 °CBrown fat activity detected in 23 of 24 subjects during cold exposure but not at thermoneutrality. Activity was significantly lower in obese subjects and correlated negatively with BMI and body-fat percentage
Virtanen and colleagues5 healthy subjects, cold-stimulated imaging with biopsies from the first threeCold-induced glucose uptake in paracervical and supraclavicular adipose tissue rose, in the abstract’s words, by a factor of 15. Biopsies showed elevated UCP1 at both mRNA and protein level, with multilocular lipid droplets

Two features of that table are worth holding onto. First, the cold-exposure finding and the routine-scan finding are very different numbers — 96% versus 7.5% — because one looked under stimulation and the other did not. Second, the inverse association with BMI appears in two of the three, and it is the origin of a great deal of subsequent hope and a certain amount of circular reasoning: less brown fat in obesity could be a cause, a consequence, or an imaging artefact.

What UCP1 actually does

Mitochondria normally pump protons out across the inner membrane during substrate oxidation, then let them back in through ATP synthase, capturing the energy as ATP. UCP1 provides a bypass. It is a carrier in the mitochondrial inner membrane that transports protons from the intermembrane space back into the matrix without passing them through ATP synthase, so the proton-motive force is dissipated as heat. The oxidation keeps running; the energy goes nowhere useful, on purpose.

The part usually left out. UCP1 is not an open hole. A 2022 paper is titled, simply, “Uncoupling Protein 1 Does Not Produce Heat without Activation” — it requires activation, typically by the free fatty acids released during lipolysis. That is why cold exposure needs the whole sympathetic cascade and not just UCP1 expression: measuring UCP1 protein tells you capacity, not activity.

The knockout experiment is where the simple story breaks. Enerbäck and colleagues reported in Nature in 1997 that mice lacking the mitochondrial uncoupling protein are, as their title has it, cold-sensitive but not obese. The animals could not thermoregulate properly and consumed less oxygen in response to a beta-3 agonist — the thermogenic defect was real — but they were not obese and not hyperphagic, on a standard diet or a high-fat diet. The authors proposed that UCP2, which was induced in the knockouts’ brown fat, might compensate.

That result is nearly thirty years old and is still the cleanest available evidence against the inference that more UCP1 means a leaner animal. It is rarely quoted in writing that promotes brown fat as a weight-loss target.

How it gets switched on

Cold is sensed, the sympathetic nervous system fires, noradrenaline is released onto adipocytes, adrenergic receptors drive lipolysis, and the resulting free fatty acids activate UCP1. That much is agreed.

Which adrenergic receptor subtype carries the signal in humans is not. In rodents, beta-3 signalling is primary. In humans the evidence conflicts. The in-vivo pharmacology points at beta-3: mirabegron, a beta-3 agonist, raised brown fat activity in people — Cypess and colleagues reported activation of human brown adipose tissue by a beta-3-adrenergic receptor agonist in 2015, and two later studies covered below confirmed and extended it. But a 2020 study in cultured human brown adipocytes and fresh human biopsies found that ADRB1 was the predominant subtype, that a beta-1-selective agonist and a pan-agonist raised UCP1 mRNA while beta-2 and beta-3 agonists did not, and that ADRB1 knockdown attenuated the response. Its title is appropriately hedged: beta-1 and not beta-3 adrenergic receptors may be the primary regulator of human brown adipocyte metabolism.

Both lines of evidence are real, and they are in tension. The honest position is that human brown fat’s adrenergic regulation differs from the mouse model and is not settled.

How cold exposure leads to heat production in brown adipose tissue A left-to-right schematic. Cold exposure triggers sympathetic nervous system firing, which releases noradrenaline onto brown adipocytes. Noradrenaline acts on adrenergic receptors, labelled as beta-3 in rodents with the human subtype marked unsettled, and drives lipolysis. Lipolysis releases free fatty acids, which are required to activate UCP1 in the mitochondrial inner membrane. Activated UCP1 lets protons return from the intermembrane space to the matrix, bypassing ATP synthase, so the proton-motive force is dissipated as heat rather than captured as ATP. A note underneath records that UCP1 protein without this activation step produces no heat, and that UCP1-knockout mice are cold-sensitive but not obese. Cold to heat: five steps, and UCP1 is only the last one Cold sympathetic firing Noradrenaline on adrenergic receptors β3 in rodents; human subtype unsettled Lipolysis free fatty acids released UCP1 activated by those fatty acids Heat not ATP Inside the mitochondrion intermembrane space (H+ high) matrix (H+ low) ATP synthase UCP1 H+ → ATP H+ → heat Simplified. UCP1 protein on its own produces no heat: without activation by lipolysis-derived free fatty acids it does not conduct protons. Measuring UCP1 expression therefore measures capacity, not thermogenesis. And capacity is not body weight: mice lacking UCP1 entirely are cold-sensitive but not obese, on a standard diet or a high-fat one.
Simplified pathway from cold exposure to UCP1-mediated heat production.

Brown, beige and browning

There is more than one kind of thermogenic adipocyte. UCP1-positive cells can also appear within white fat depots, a phenomenon called browning, and those cells are referred to as beige or brite adipocytes. Wu and colleagues reported in Cell in 2012 that beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.

A 2013 review in Nature Medicine draws the functional line cleanly: brown adipocytes occupy dedicated depots and constitutively express high levels of thermogenic genes, while beige adipocytes are inducible and develop within white fat in response to various activators. Whether they are also developmentally distinct is a separate claim, and the cleanest supporting evidence comes from a different direction: Seale and colleagues’ 2008 Nature paper used in-vivo fate mapping to show that brown fat cells, but not white fat cells, arise from Myf5-expressing precursors — the same lineage as skeletal muscle.

That 2008 paper also identified the master regulator. PRDM16, it reported, controls a bidirectional cell-fate switch between skeletal myoblasts and brown fat cells: remove it from brown fat precursors and they drift towards muscle; express it in myoblasts and they become brown adipocytes. Prdm16-deficient brown fat showed abnormal morphology and reduced thermogenic gene expression. A 2011 companion paper established PRDM16’s role on the beige side, determining the thermogenic programme of subcutaneous white adipose tissue in mice. Upstream of all of it sits PGC-1α, described in 1998 as a cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis — the same coactivator that turns up in AMPK signalling.

Why the imaging is harder than it looks

Nearly everything known about human brown fat comes from cold-stimulated 18F-FDG PET/CT, and that method measures glucose uptake. The field has standardised how to report it — a 2016 multi-author consensus set out the Brown Adipose Reporting Criteria in Imaging STudies, BARCIST 1.0 — but standardisation does not fix the underlying mismatch.

A 2018 review in Frontiers in Endocrinology states it directly: FDG-PET/CT remains the gold standard for identifying brown fat, but brown fat glucose metabolism does not accurately reflect brown fat thermogenic activity. Much of the glucose taken up is not oxidised — roughly half is released as lactate — so uptake can be disconnected from heat production altogether. Uptake also tracks insulin sensitivity and blood flow, is especially unreliable in obesity and type 2 diabetes, and is affected by outdoor temperature, age, sex, adiposity, circadian rhythm and drugs such as beta-blockers. Depots under one cubic centimetre are hard to quantify at all, so the method likely underestimates true brown fat volume, particularly in people with obesity and diabetes. A 2026 review makes the same point more bluntly: FDG-PET measures glucose utilisation, not UCP1-mediated proton conductance.

This matters for reading any brown-fat result. “Brown fat activity increased” in almost every human study means “glucose uptake into brown fat increased”, which is a reasonable proxy and not the same thing.

How much energy it actually burns

This is where the gap between the literature and the marketing is widest, and the honest answer requires being specific about what is measured and what is assumed.

The 2018 review gives no single figure for adult brown fat mass. It notes that the total volume of FDG-positive brown fat amounts to under about 150 ml in most healthy individuals, and for its own calculations it uses assumed working values of 150 g and 168 g. It argues those are probably underestimates, citing a three-dimensional mapping study with a range of 510 to 2,358 ml — but that larger figure refers to brown-fat-containing adipose tissue, not brown fat itself, and the two are routinely conflated.

EstimateFigureBasis
Directly measured energy expenditureAbout 7 to 25 kcal per day15O2 PET at room temperature or during mild cold
Scaled up, room temperature27 to 123 kcal per dayCalculated using larger assumed brown fat volumes
Scaled up, mild cold46 to 211 kcal per daySame assumption, under cold stimulation

The review’s own verdict on this range is that current estimates sit at the lower end of what could be clinically relevant if sustained. The direct measurements are the trustworthy end of the table; the scaled figures inherit all the uncertainty in the volume term.

The largest observational study points the other way, and is worth reading carefully for that reason. Becher and colleagues reviewed 134,529 FDG-PET/CT scans from 52,487 patients in Nature Medicine in 2021 and found that brown fat presence was associated with a lower prevalence of cardiometabolic disease, independently correlating with lower odds of type 2 diabetes, dyslipidaemia, coronary artery disease, cerebrovascular disease, congestive heart failure and hypertension, with associations stronger in people with overweight or obesity. It is a genuinely striking dataset. It is also retrospective, correlational, and conducted on scans performed for cancer care without cold stimulation — and brown fat detectability on an unstimulated scan is itself confounded by age, adiposity, medication and ambient temperature. The authors claim only a potential role for brown fat in promoting cardiometabolic health, and that is the right strength of claim.

The irisin cautionary tale

No account of this field is complete without irisin, because it shows how fast a browning story can travel and how hard it is to retract.

In 2012, Boström and colleagues published in Nature a paper titled “A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis” — note the exact title, which is frequently misquoted as “drives browning of white fat”. The proposed hormone, irisin, released from muscle during exercise and browning white fat, was an irresistible mechanism for why exercise is good for you.

Two problems emerged. The first is measurement. A 2015 paper in Scientific Reports, titled “Irisin — a myth rather than an exercise-inducible myokine”, tested four commercial antibodies and found that in human and animal sera they produced strong bands from cross-reacting non-specific proteins with none at the expected irisin size; that irisin results from two different ELISA kits did not correlate with each other; and that mass spectrometry of immunoprecipitated bands found no irisin peptides, with apolipoprotein A1 the predominant protein instead. The second is translation. A 2013 PLOS ONE paper, “Evidence against a Beneficial Effect of Irisin in Humans”, reported that the human FNDC5 gene carries a mutation in the conserved start codon, ATG to ATA, and that a human construct using ATA produced only 1% full-length protein.

The defensible conclusion is narrower than either the hype or the backlash. Commercial ELISA measurements of circulating irisin are unreliable, and the translation of the mouse findings to humans is in serious doubt. It is not that irisin does not exist: the same 2015 paper identified a unique irisin peptide at the correct size in unspiked human serum by mass spectrometry — below the detection limit of the antibodies it had just discredited. Our guide to reading a peptide study covers why assay validation is the least glamorous and most load-bearing part of a paper.

What the “thermogenic” compounds actually do

Several research compounds are routinely described as thermogenic or as brown-fat activators. We went through the primary papers for the four most often filed that way. None of them reports a brown fat or UCP1 mechanism.

CompoundWhat the primary papers actually reportBrown fat or UCP1?
5-Amino-1MQ (NNMT inhibitor)A 2014 Nature paper found NNMT knockdown in white adipose tissue and liver protected against diet-induced obesity, attributing it to raised adipose SAM and NAD+, increased polyamine flux and greater energy expenditure. A 2018 paper reported that a methylquinolinium inhibitor reduced body weight and white adipose mass in high-fat-diet mice with no change in food intakeNo. Both studied white adipose tissue; neither abstract mentions brown fat, UCP1 or thermogenesis
SLU-PP-332 (pan-ERR agonist)A 2023 paper reported increased mitochondrial function in a skeletal-muscle cell line, more type IIa oxidative fibres and improved endurance in mice, through an ERRα-dependent acute exercise gene programme. A 2024 paper reported increased energy expenditure and fatty-acid oxidation and reduced fat-mass accumulation in obese miceNo. The verified mechanism is skeletal-muscle and ERRα-mediated; neither paper’s abstract mentions brown fat, UCP1 or thermogenesis
AOD-9604 (hGH fragment 176–191)A 2001 paper found weight loss and increased lipolytic sensitivity in obese mice, correlating with increased beta-3 receptor mRNA in adipose tissue — but in beta-3-knockout mice chronic treatment produced no such changes, and the authors concluded its actions are not mediated directly through beta-3 receptors. Human work is safety and tolerability only; a 2010 review records that after a phase IIB clinical trial the results did not support the commercial viability of the drug as a treatment for obesityNo. No source we reached mentions brown fat or UCP1
Adipotide (FTPP)A 2004 Nature Medicine paper identified a peptide targeting the blood vessels of white fat, binding prohibitin; coupling a pro-apoptotic sequence to it destroyed white fat and reversed obesity in mice. A 2011 study in obese monkeys confirmed it induced targeted apoptosis within blood vessels within white adipose tissue, and reported predictable reversible changes in renal proximal tubule functionNo. The mechanism is targeted destruction of white fat vasculature. It is not a thermogenic agent in any sense

The conflation to watch for. Several of these papers report increased energy expenditure. That is not the same as thermogenesis via brown fat, and it is the single most likely accuracy failure in writing on this subject. Energy expenditure can rise through muscle work, substrate cycling, or any number of routes that have nothing to do with UCP1. A paper reporting higher oxygen consumption has not thereby reported brown fat activation.

Our individual guides cover each compound on its own evidence: 5-Amino-1MQ, SLU-PP-332 and AOD-9604.

What’s established and what isn’t

Reasonably well established

  • Adult humans have functional, UCP1-expressing brown adipose tissue, mainly in neck and supraclavicular depots.
  • Cold exposure activates it: 23 of 24 healthy men showed activity at 16 °C and none at thermoneutrality.
  • UCP1 is a mitochondrial inner-membrane carrier that dissipates the proton-motive force as heat, and it requires activation by lipolysis-derived free fatty acids.
  • UCP1-knockout mice are cold-sensitive but not obese on either a standard or a high-fat diet.
  • Beige adipocytes are inducible UCP1-positive cells within white depots; brown adipocytes arise from Myf5-expressing precursors and beige ones do not.
  • PRDM16 controls a brown fat / skeletal muscle fate switch, and determines the thermogenic programme of subcutaneous white fat.
  • FDG-PET measures glucose uptake, not heat production, and about half the glucose brown fat takes up is released as lactate.
  • Directly measured brown fat energy expenditure is roughly 7 to 25 kcal per day.
  • No drug approved anywhere works by activating brown fat.

Open questions

  • Which adrenergic receptor subtype is primary in human brown fat. In-vivo beta-3 pharmacology and in-vitro beta-1 data point in different directions.
  • How much brown fat adults actually have. The volume term is the largest source of uncertainty in every energy calculation.
  • Whether the association between brown fat and better cardiometabolic health is causal. The largest study is retrospective and its authors claim only a potential role.
  • Whether brown fat activation can be made therapeutic at a tolerable cardiovascular cost. The only drug tested needed a higher-than-approved dose and raised heart rate and blood pressure.
  • Whether browning white fat can meaningfully change body weight in humans. Chronic beta-3 agonist treatment raised energy expenditure with no change in body weight or body composition.
  • Whether human irisin does anything. Measurement is unreliable and the human start-codon variant yields about 1% full-length protein.
  • Whether any research compound marketed as thermogenic has a brown fat mechanism. None of the four examined here does.

Sourcing metabolic reagents in Canada

Metabolic-research reagents raise one documentation point that peptide work alone does not: several of the compounds in this area are small molecules rather than peptides, and the analytical evidence should match the molecule.

5-Amino-1MQ research vial from Pure Peptides Canada5-Amino-1MQAn NNMT inhibitor; the published work is in white fat, not brownView product SLU-PP-332 research product from Pure Peptides CanadaSLU-PP-332An ERR agonist acting on skeletal muscle, not UCP1View product AOD-9604 research vial from Pure Peptides CanadaAOD-9604A growth hormone fragment; its actions are not beta-3 mediatedView product Adipotide research vial from Pure Peptides CanadaAdipotideTargets white fat vasculature via prohibitin — not thermogenicView product
Independent testingJanoshik Analytical certificates, listed by batch on our Lab Testing page.
Check your batchMatch the batch number on your vial to its report.
Tracked, discreet shippingCanada-wide by Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
Priced in CADShipped from inside Canada.

Research use only. Pure Peptides Canada products are laboratory reagents for in-vitro research, not for human or veterinary use. This article explains published research for education; it is not medical, dietary or dosing guidance.

Frequently asked questions

What is brown adipose tissue?

Brown adipose tissue is a fat depot whose job is to produce heat rather than store energy. Its cells are packed with mitochondria and hold many small lipid droplets instead of one large one, which is why biopsies describe them as multilocular. In adults the main depots are in the neck and supraclavicular region. Its defining protein is UCP1, which allows mitochondria to dissipate energy as heat instead of capturing it as ATP.

Do adults have brown fat?

Yes. Three studies published in the same 2009 issue of the New England Journal of Medicine established it. One detected brown fat activity in 23 of 24 healthy young men during mild cold exposure at 16 degrees Celsius but not at thermoneutrality. Another, reviewing 3,640 routine scans from 1,972 patients, found substantial brown fat in 7.5% of women and 3.1% of men, with biopsies confirming UCP1-positive multilocular adipocytes. A third reported that cold-induced glucose uptake into those depots rose by a factor of 15.

What does UCP1 do?

UCP1 is a carrier protein in the mitochondrial inner membrane. Mitochondria normally pump protons out during substrate oxidation and let them back in through ATP synthase, capturing the energy as ATP. UCP1 provides a bypass, letting protons return to the matrix directly, so the proton-motive force is dissipated as heat instead. Importantly it does not conduct protons constantly: it requires activation, typically by the free fatty acids released during lipolysis.

Does more brown fat mean a leaner body?

The evidence does not support that simple inference. Mice lacking UCP1 entirely were reported in 1997 to be cold-sensitive but not obese, and not hyperphagic, on either a standard or a high-fat diet. In humans, brown fat presence is associated with lower prevalence of cardiometabolic disease in a large retrospective study, but that analysis is correlational and its authors claim only a potential role. Chronic beta-3 agonist treatment raised energy expenditure with no change in body weight or body composition.

How much energy does brown fat actually burn?

Less than most accounts suggest. Direct measurement using oxygen-15 PET at room temperature or during mild cold gives estimates of roughly 7 to 25 kcal per day. Scaled-up calculations using larger assumed brown fat volumes give 27 to 123 kcal per day at room temperature and 46 to 211 kcal per day during mild cold, but those figures inherit all the uncertainty in the volume estimate, and the review that produced them concludes that current estimates sit at the lower end of what could be clinically relevant.

Does FDG-PET measure brown fat heat production?

No. It measures glucose uptake, which is a proxy. A 2018 review states that brown fat glucose metabolism does not accurately reflect its thermogenic activity, noting that roughly half the glucose taken up is released as lactate rather than oxidised. Uptake also tracks insulin sensitivity and blood flow, and is affected by ambient temperature, age, sex, adiposity, circadian rhythm and drugs such as beta-blockers.

Do 5-Amino-1MQ, SLU-PP-332, AOD-9604 or adipotide activate brown fat?

No. None of the primary papers for these compounds reports a brown fat or UCP1 mechanism. The NNMT work behind 5-Amino-1MQ studied white adipose tissue; SLU-PP-332’s verified mechanism is ERR-alpha signalling in skeletal muscle; AOD-9604’s actions were found not to be mediated directly through beta-3 receptors, and its only human trial results are safety and tolerability data; and adipotide works by targeted destruction of white fat vasculature via prohibitin. Several of these papers report increased energy expenditure, which is not the same thing as thermogenesis via brown fat.

Metabolic research reagents, documented by batch

5-Amino-1MQ, AOD-9604, adipotide and the rest of the metabolic range, priced in Canadian dollars and shipped tracked from inside Canada.

Browse weight loss & metabolicRead: the AMPK guide

Related reading

References

  1. Enerbäck S, Jacobsson A, Simpson EM, Guerra C, Yamashita H, Harper M-E, Kozak LP. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature. 1997;387(6628):90–94. DOI
  2. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92(6):829–839. DOI
  3. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang W-J, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. DOI
  4. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625–632. DOI
  5. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng Y-H, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509–1517. DOI
  6. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JMAFL, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJJ. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360(15):1500–1508. DOI
  7. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto N-J, Enerbäck S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360(15):1518–1525. DOI
  8. Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008;454(7207):961–967. DOI
  9. Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals. 2010;3(1):125–145. DOI
  10. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J, Cohen P, Cinti S, Spiegelman BM. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest. 2011;121(1):96–105. DOI
  11. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112. DOI
  12. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468. DOI
  13. Wu J, Boström P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150(2):366–376. DOI
  14. Raschke S, Elsen M, Gassenhuber H, et al. Evidence against a beneficial effect of irisin in humans. PLoS ONE. 2013;8(9):e73680. DOI
  15. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19(10):1252–1263. DOI
  16. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7–15. DOI
  17. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. DOI
  18. Albrecht E, Norheim F, Thiede B, et al. Irisin — a myth rather than an exercise-inducible myokine. Sci Rep. 2015;5:8889. DOI
  19. Cypess AM, Weiner LS, Roberts-Toler C, et al. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab. 2015;21(1):33–38. DOI
  20. Solmonson A, Mills EM. Uncoupling proteins and the molecular mechanisms of thyroid thermogenesis. Endocrinology. 2016;157(2):455–462. DOI
  21. Chen KY, Cypess AM, Laughlin MR, et al. Brown adipose reporting criteria in imaging studies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans. Cell Metab. 2016;24(2):210–222. DOI
  22. Neelakantan H, Vance V, Wetzel MD, Wang HYL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141–152. DOI
  23. Baskin AS, Linderman JD, Brychta RJ, et al. Regulation of human adipose tissue activation, gallbladder size, and bile acid metabolism by a β3-adrenergic receptor agonist. Diabetes. 2018;67(10):2113–2125. DOI
  24. Carpentier AC, Blondin DP, Virtanen KA, Richard D, Haman F, Turcotte ÉE. Brown adipose tissue energy metabolism in humans. Front Endocrinol. 2018;9:447. DOI
  25. Riis-Vestergaard MJ, Richelsen B, Bruun JM, Li W, Hansen JB, Pedersen SB. Beta-1 and not beta-3 adrenergic receptors may be the primary regulator of human brown adipocyte metabolism. J Clin Endocrinol Metab. 2020;105(4):e994–e1005. DOI
  26. O’Mara AE, Johnson JW, Linderman JD, et al. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020;130(5):2209–2219. DOI
  27. Becher T, Palanisamy S, Kramer DJ, et al. Brown adipose tissue is associated with cardiometabolic health. Nat Med. 2021;27(1):58–65. DOI
  28. Li Y, Fromme T. Uncoupling protein 1 does not produce heat without activation. Int J Mol Sci. 2022;23(5):2406. DOI
  29. Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756–771. DOI
  30. Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232–240. DOI
  31. Yan M, Wang H, Sha W, Fu Y. UCP1-dependent thermogenic adipose tissue in human disease: adipose-centered mechanisms, biomarker limitations, and translational perspectives. Int J Mol Sci. 2026;27(14):6416. DOI
  32. US Food and Drug Administration. MYRBETRIQ (mirabegron) prescribing information, NDA 202611, listing overactive bladder and paediatric neurogenic detrusor overactivity as its only indications.

For laboratory research use only. Not for human or veterinary use. This article summarizes published research for educational purposes and is not medical advice.